secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-07-02T23:59:59+00:00
Accession:  0001641172-25-017557
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Mira-55 shows morphine-comparable pain relief in animal model; SKNY acquisition clears SEC review
--------------------------------------------------------------------------------

- Mira-55, a non-psychoactive marijuana analog, matched morphine's pain relief in a formalin-based rodent model without sedation or inflammation.
- DEA previously confirmed Mira-55 is not a controlled substance, removing a key regulatory barrier to clinical development.
- SEC completed review of merger proxy for SKNY Pharmaceuticals acquisition with no comments, enabling shareholder vote.
- SKNY-1, the target therapy, demonstrated 30% body weight reduction without muscle loss and reversal of nicotine cravings in recent studies.
- MIRA advancing Mira-55 toward IND submission for inflammatory pain indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225017557/0001641172-25-017557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225017557/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-017557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer